Preliminary Program subject to change
T2001 Control of polymorphism of APIs or broader value-added materials
OverviewDifferent polymorphs of the same chemical entity display distinct physical properties, such as melting point, solubility, dissolution rate, hygroscopicity, stability, etc. The ability to successfully produce and reproduce specific polymorphic modifications is intricately correlated with the efficiency and speed of materials development, the robustness of manufacturing process, and – ultimately – the stability and quality of the targeted value-added materials. Papers are invited on all aspects of the control of polymorphism and pseudopolymorphism, applicable to pharmaceutical development or manufacture of other value-added materials.
Primary SponsorTopical 2: Discover, Development and Delivery of Medicines (T2)
Co-Sponsor(s)Crystallization and Evaporation (02b), Pharmaceuticals (See also Topical 2) (15b)

Chair

Peter Karpinski
Senior Principal Fellow
Novartis Pharmaceuticals Corp.
One Health Plaza 436-2253
East Hanover, NJ 07936-1080
Phone Number: (862) 778-4903
Fax Number: (973) 781-6574
Email: peter.karpinski@novartis.com

CoChair

Sridhar Desikan
Bristol-Meyers Squibb
Pharmaceutical Research Institute
One Squibb Drive
New Brunswick, NJ 08903-0191
Phone Number: (732) 227-6133
Fax Number: (732) 227-3782
Email: sridhar.desikan@bms.com
Introductory Remarks
Effective Evaluation of Solid-Phase Free Energies
Nancy Cribbin, Andrew J. Schultz, Kenneth M. Benjamin and David A. Kofke, Chemical and Biological Engineering, University of Buffalo, 303 Furnas Hall, SUNY at Buffalo, Buffalo, NY 14260
Impact of Phase Split Ratio on Agglomeration Behavior in an Api Crystallization
Shekhar K. Viswanath, Ahmad Sheikh, John Tolle, Agnes Pal and James Marek, Process R&D, Abbott Labs, 1401 Sheridan Road, R13-3, North Chicago, IL 60064
Investigation on Polymorphic Transformations of Api Using Raman Spectroscopy
Lili Feng, Chemical & Analytical Development, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, Zhaoxia Liu, Novartis Pharmaceutical Corporation, East Hanover, NJ 07936 and Peter Karpinski, Novartis Pharmaceuticals Corp., One Health Plaza 436/2253, East Hanover, NJ 07963-1080
The Kinetics of L-Glutamic Acid Precipitation: Characterization and Modeling
Marco Mazzotti1, Lars Vicum1, Christian Lindenberg1, Jochen Schöll1 and Jörg Brozio2, (1)Institute of Process Engineering, ETH Zurich, Zurich, Switzerland, (2)Chemical & Analytical Development, Novartis Pharma AG, Basel, CH-4002
Polymorphism in the Crystallization of Glycine
Xia Yang, Chi Bun Ching, Xiu Juan Wang and Jie Lu, School of Chemical and Biomolecular Engineering, Nanyang Technology University, Nanyang Avenue, Singapore, Singapore, Singapore
Direct Growth of Gamma Glycine from Neutral Aqueous Solutions by Slow, Evaporation-Driven Evaporation
Paul J. A. Kenis1, Guangwen He2, Venkateswarlu Bhamidi3, Scott R. Wilson4, Reginald B. H. Tan5 and Charles F. Zukoski2, (1)Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana, IL 61801, (2)Department of Chemical & Biomolecular Engineering, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana, IL 61801, (3)Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana - Champaign / ICES, Singapore, 600 S. Mathews Ave., Urbana, IL 61801, (4)School of Chemical Sciences, University of Illinois at Urbana-Champaign, 600 S. Mathews Ave., Urbana, IL 61801, (5)Department of Chemical & Biomolecular Engineering, National University of Singapore, 4 Engineering Drive 4, Singapore, 117576
Concluding Remarks

Topical 2: Discovery, Development and Delivery of Medicines